-
1 Comment
Jianmin Pharmaceutical Group Co., Ltd is currently in a long term uptrend where the price is trading 67.8% above its 200 day moving average.
From a valuation standpoint, the stock is 83.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.6.
Jianmin Pharmaceutical Group Co., Ltd's total revenue rose by 108.9% to $850M since the same quarter in the previous year.
Its net income has increased by 21.9% to $22M since the same quarter in the previous year.
Finally, its free cash flow fell by 22.8% to $47M since the same quarter in the previous year.
Based on the above factors, Jianmin Pharmaceutical Group Co., Ltd gets an overall score of 4/5.
| ISIN | CNE000001HB7 |
|---|---|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Exchange | SHG |
| CurrencyCode | CNY |
| Market Cap | 6B |
|---|---|
| Beta | 0.71 |
| PE Ratio | 16.68 |
| Target Price | 87.74 |
| Dividend Yield | None |
Jianmin Pharmaceutical Group Co.,Ltd. manufactures and sells medicines in China. It offers medicines and pediatric drugs under the Jianmin, Longmu, and Yekaitai brand name. The company provides OTC, medical, and general health products, as well as consultation service. Jianmin Pharmaceutical Group Co.,Ltd. was founded in 1993 and is headquartered in Wuhan, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 600976.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
